The DOI matches its Crossref record.
ES28.04 Emerging Mechanisms to Target KRAS Directly
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
mRNA-5671/V941 targets the G12D, G12V, G13D and G12C KRAS variants and has a strong mechanistic rationale.
“mRNA-5671/V941, a liquid nanoparticle-formulated mRNA neoantigen vaccine that targets the G12D, G12V, G13D and G12C variants of KRAS, has been developed and has strong mechanistic rationale196.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [196]
Citations
Cited by
Sorted by citations
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Metadata
- Authors
- Nagasaka, M.
- Affiliations
- The Barbara Ann Karmanos Cancer Institute (US)
- Corresponding author
- Nagasaka, M.
- ORCID
- Nagasaka, M.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 16
- Issue
- 3
- Pages
- S96-S97
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3138837374
- Cited by
- 15
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 1
- Type
- conference abstract
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS mutation, non-small cell lung cancer, KRAS G12C inhibitors, covalent KRAS inhibitor, PROTACs, CRISPR/Cas9, adoptive T cell therapy, cancer vaccines, KRAS-targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
